Hanger Inc

Hanger — Investor Presentation (May 2020)

38 slides from Hanger's investor presentation, May 18, 2020

  1. Slide 1: Investor Presentation May 2020

    Investor Presentation May 2020 E M P O W E R I N G H U M A N P O T E N T I A L

  2. Slide 2: Cautionary Note Forward Looking Statements

    Cautionary Note Forward Looking Statements This presentation contains statements that are forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include information concerning our liquidity and our possible or assumed future results of operations, in

  3. Slide 3: Agenda

    Agenda Company Overview The Orthotics and Prosthetics Market Patient Care Segment Products and Services Segment Financial Performance 3 E M P O W E R I N G H U M A N P O T E N T I A L

  4. Slide 4: Company Overview

    CompanyOverview E M P O W E R I N G H U M A N P O T E N T I A L

  5. Slide 5: Hanger At a Glance

    Hanger At Glance WHO WE ARE • • • • Industry leader in orthotics & prosthetics services $4.3 billion1 addressable O&P domestic U.S. market Pioneered prosthetic devices in 1861 Focus on custom devices BY THE NUMBERS3 • • • • • Net Revenue $1.098 billion Adjusted EBITDA2 $124.2 million 4,800 FTEs 804

  6. Slide 6: Hanger Values, Vision and Purpose

    Hanger Values, Vision and Purpose O U R V A L U E S Patient-focused, integrity, outcomes, collaboration, innovation – are the heartbeat of a cultural evolution that places our patients at the core of everything we do O U R V I S I O N To lead the orthotic and prosthetic markets by providing superior

  7. Slide 7: Business Mix

    Business Mix Primary Focus on the Provision of Specialty Health Care Net Revenue1 $1.098 BILLION Adjusted EBITDA1, 2 $124.2 MILLION – 11.3% EBITDA MARGIN Patient Care $164.6 million 18.2% margin Patient Care $905.7 million 82.5% revenue Products & Ser vices $192.4 million 17.5% revenue Corporate & O

  8. Slide 8: Investment Thesis

    Investment Thesis Industry Leader Building Sustainable Competitive Advantage M A R K E T L E A D E R S I Z E A B L E M A R K E T D I F F E R E N T I A T O R S G R O W T H L E V E R S The leading provider of orthotic and prosthetic services in the United States $4.3 billion market for prescription pr

  9. Slide 9: The Orthotics and Prosthetics Market

    TheOrthotics and ProstheticsMarket E M P O W E R I N G H U M A N P O T E N T I A L

  10. Slide 10: Orthotics

    Orthotics Approximately 45% of Patient Care Revenue • Orthotic devices modify the structural and functional characteristics of the neuromuscular and skeletal system Prescribed for injuries, musculoskeletal, neurological or orthopedic disorders Hanger Clinic emphasizes fabrication of customized devic

  11. Slide 11: Prosthetics

    Prosthetics Approximately 55% of Patient Care Revenue • Prosthetic devices replace a missing limb or portion of a limb Provided to patients with amputated or congenitally absent limbs to replace the function and appearance of a limb Prosthetics are customized to meet the unique location and characte

  12. Slide 12: Prosthetics: Large & Growing Addressable Market

    Prosthetics: Large & Growing Addressable Market Approximately 500,000 People Living with Major Limb Loss in the U.S. • Approximately 350,000 people with major limb loss utilize a prosthesis Over 90% are lower extremity Traumatic amputations tend to have a positive long-term prognosis Typically have

  13. Slide 13: O&P Market: $4.3 Billion Diverse Disease State Mix Drives Demand

    O&P Market: $4.3 billion Diverse Disease State Mix Drives Demand Injuries Approximately 76,000 major amputations per year, 5-10% of which are due to injury. +$1 billion spent on prosthetics secondary to injury Endocrine & Circulatory Endocrine and circulatory disorders drive the majority of major am

  14. Slide 14: Patient Care Segment

    Patient CareSegment E M P O W E R I N G H U M A N P O T E N T I A L

  15. Slide 15: Patient Care Segment

    Patient Care Segment Building Sustainable Advantages in a Fragmented Industry • • National network and market leadership Unique ability to measure and improve patient outcomes Driving patient engagement, connectivity and satisfaction Optimizing reimbursement through centralized revenue cycle managem

  16. Slide 16: General Lower Extremity Patient Rehab Timeline

    General Lower Extremity Patient Rehab Timeline Hanger provides comprehensive patient care for a lifetime Pre-Op Post-Op Recovery Healing Initial Device Maturation Definitive Device Holistic Care Schedule • Apply post-op protector • Remove sutures • Incision fully healed • Fit first prosthesis • Limb

  17. Slide 17: Scale as a Competitive Advantage

    Scale as a Competitive Advantage National Network Brings Hanger Closer to the Community 8 0 0 + PAT I E N T C A R E L O C AT I O N S 1 , 6 0 0 C L I N I C I A N S Hanger employs over 20% of the board certified O&P clinicians in the U.S. Competitors are spread out in small local practitioner settings

  18. Slide 18: Market Leader in a Fragmented Industry

    Market Leader In a Fragmented Industry • Hanger currently operates 804 patient care locations nationally O&P Patient Care Clinic Market (by location) • • 694 patient care clinics 110 satellite locations Veteran’s Administration • • • 21% of private O&P clinics in the nation VA: Next largest at 2% Re

  19. Slide 19: Patient Engagement & Connectivity

    Patient Engagement & Connectivity Enhance Consistency, Quality of Patient Experience Strategic initiatives that engage and connect our community, measure and improve patient satisfaction, driving growth • • • Clinician and peer visitors Net promoter score: Average of 84 (Healthcare industry average

  20. Slide 20: Clinical Focus on Patient Outcomes

    Clinical Focus Implementing Clinical on Patient Outcomes Care Standards and Demonstrating Value C L I N I C A L T E A M A N D S E N I O R L E A D E R S H I P T E C H N O L O G Y A N D P R O C E S S Enterprise-wide electronic health record captures more O&P clinical outcomes than any other source Imp

  21. Slide 21: Revenue Cycle Management

    Revenue Cycle Management Central Function Drives Disallowed Revenue Lower • Operate within DMEPOS fee schedules • O&P requires highly specialized customized devices • Patient population is high acuity (similar to an acute setting) with volume of ambulatory care Importance of detailed documentation a

  22. Slide 22: Advancing Supply Chain Capabilities

    Advancing Supply Chain Capabilities Transforming Through Technology and Process Re-engineering Industry Leading Product Selection Same-Day Shipments 90+% E-Commerce Ordering Enhanced Product Descriptions & Website Features Vendor Consignment Lower excess shipment costs through inventory optimization

  23. Slide 23: Products and Services Segment

    Productsand ServicesSegment E M P O W E R I N G H U M A N P O T E N T I A L

  24. Slide 24: Products and Services

    Products and Ser vices National Scale Supports Profitable Growth Distribution of O&P components & related devices through SPS (75% of segment net revenue) Patient Care Products & Services $192.4 million 17.5% revenue • • • 5.4% net revenue growth in 2019 Comprehensive catalog for independent O&P pro

  25. Slide 25: Financial Performance

    FinancialPerformance E M P O W E R I N G H U M A N P O T E N T I A L

  26. Slide 26: Growth Model

    Growth Model Two-Fold Approach D R I V E O R G A N I C R E V E N U E G R O W T H S E L E C T, I N - M A R K E T A C Q U I S I T I O N S Exceed industr y growth rate of 1.5 - 2.0% Disciplined approach to O&P acquisitions • • • • Increase referral volumes through differentiation Focus on high-value cu

  27. Slide 27: Financial Results: Annual Revenue Performance

    Financial Results $ millions First Quarter 2020 and 2019 Annual Revenue Performance P A T I E N T C A R E H A S D R I V E N R E V E N U E G R O W T H Y E A R 2 0 1 9 F I R S T Q U A R T E R ‘ 2 0 $1,098.0 • 2019: Patient Care segment grew 5.6%; 2019 annual same clinic, day-adjusted growth of 2.1%, w

  28. Slide 28: Financial Results: Adjusted EBITDA Performance

    Financial Results $ millions Adjusted EBITDA1 Performance First Quarter 2020 and 2019 Annual F I R S T Q U A R T E R ‘ 2 0 Y E A R $121.1 2 0 1 9 $124.2 P A T I E N T C A R E H A S D R I V E N R E V E N U E G R O W T H • In 2019, growth in Patient Care segment Adjusted EBITDA was 9.1% and Adjusted E

  29. Slide 29: Same Clinic Rate of Growth

    Same Clinic Rate of Growth Net Revenue on Per Day Basis Quarterly % Change1 3.0% 2.9% 1.7% 1.1% 0.6% -3.2% Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q419 Q1 20 1Same clinic revenue growth per day excludes the effect of change in rate of disallowances for 2017. Beginning in 20

  30. Slide 30: Payor Mix and Accounts Receivable Trend

    Payor Mix and Accounts Receivable Trend Multi-Year Improvements in Working Capital Conversion Payor Mix, Percentage of Patient Care Net Revenue1 Accounts Receivable, net (green bars) $ millions Day Sales Outstanding (orange line) 60 55 50 45 40 35 30 200 180 160 140 120 100 80 60 40 20 0 DSO 48 and

  31. Slide 31: Cash Flow, Liquidity & Capital Allocation Priorities

    Cash Flow, Liquidity & Capital Allocation Priorities Conserve Cash During COVID-19 to Manage Through Economic Downturn C U R R E N T C O V E N A N T S T R U C T U R E P R E - C O V I D - 1 9 C A S H F L O W C U R R E N T B A L A N C E S H E E T Q1 20201 Net Cash Flow (Adjusted EBITDA2 - CapEx) of $8

  32. Slide 32: COVID-19 Update

    COVID-19 Update Strategy to Manage Through The Challenge and Ultimately Thrive P R O T E C T I N G O U R P E O P L E S E R V I N G O U R P A T I E N T S C O N S E R V I N G C A P I T A L • COVID-19 Crisis Management Team, formed in January 2020, to ensure employee and patient safety, ensure business

  33. Slide 33: Investment Thesis

    Investment Thesis Industry Leader Building Sustainable Competitive Advantage M A R K E T L E A D E R S I Z E A B L E M A R K E T D I F F E R E N T I A T O R S G R O W T H L E V E R S The leading provider of orthotic and prosthetic services in the United States $4.3 billion market for prescription pr

  34. Slide 34: Appendix Non-GAAP Reconciliations

    AppendixNon-GAAP Reconciliations E M P O W E R I N G H U M A N P O T E N T I A L

  35. Slide 35: Net Income to Adjusted EBITDA 2019-2017

    Net Income to Adjusted EBITDA 2019-2017 For the Ye a rs Ende d De ce mber 31, 2019 2018 2017 Net income (loss) - as reported (GAAP) $ 27,525 (858) (104,671) Adjustments to calculate EBITDA: Depreciation and amortization Interest expense, net Loss on extinguishment of debt Non-service defined benefit

  36. Slide 36: Net Income to Adjusted EBITDA TTM March 2020 v. 2019

    Net Income to Adjusted EBITDA TTM March 31 2020 v. TTM March 31 2019 For the Twelve Months Ended March 31, 2020 2019 Net loss - as reported (GAAP) $ 18,728 $ 14,809 Adjustments to calculate EBITDA: Depreciation and amortization Interest expense, net Loss on extinguishment of debt Non-service defined

  37. Slide 37: Net Income to Segment Adjusted EBITDA

    Net Income to Segment Adjusted EBITDA For the Three Months Ended For the Years Ended March 31, December 31, 2020 2019 2019 2018 Patient Care Income from operations - as reported (GAAP) Depreciation & amortization EBITDA (Non-GAAP) Further adjustments to calculate Adjusted EBITDA: Equity based compen

  38. Slide 38: Adjusted EBITDA Margin: First Quarter 2020 v. 2019 and Year 2019 v. 2018

    Adjusted EBITDA Margin: First Quarter 2020 v. 2019 and Year 2019 v. 2018 For the Three Months Ended For the Years Ended March 31, December 31, 2020 2019 2019 2018 Net Revenue (a) Patient Care Products & Services Net revenue $ 190,183 $ 190,601 $ 905,691 $ 857,382 43,556 45,818 192,355 191,378 $ 233,

Hanger — Investor Presentation (May 2020) on 6ix